SCHEMBL6784765

SCHEMBL6784765

COc1ccccc1S(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.50
CA2 P00918 4/20 0.50
CA7 P43166 3/20 0.50
CA9 Q16790 3/20 0.50
CA12 O43570 2/20 0.50
CA14 Q9ULX7 2/20 0.50
CA4 P22748 1/20 0.50
TP53 P04637 2/20 0.46
TSHR P16473 1/20 0.46
ALDH1A1 P00352 4/20 0.45
POLB P06746 2/20 0.45
ENPP2 Q13822 1/20 0.43
ORAI1 Q96D31 1/20 0.42
ORAI2 Q96SN7 1/20 0.42
ORAI3 Q9BRQ5 1/20 0.42
ADRA2B P18089 1/20 0.41
PTGS1 P23219 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30785063 1.00 CA1 (0.50) CA1CA2CA7CA9CA12
SCHEMBL28392341 0.98 CA1 (0.48) CA1CA2CA7CA9CA12
SCHEMBL7509528 0.98 CA1 (0.48) CA1CA2CA7CA9CA12
SCHEMBL11306042 0.98 CA1 (0.48) CA1CA2CA7CA9CA12
SCHEMBL7509892 0.98 CA1 (0.48) CA1CA2CA7CA9CA12
SCHEMBL7521503 0.98 CA1 (0.48) CA1CA2CA7CA9CA12
SCHEMBL27509890 0.84 APP (0.44) CA1CA2CA7CA9CA12
SCHEMBL6535599 0.82 NFE2L2 (0.45) CA1CA2CA7CA9CA12
SCHEMBL23110588 0.80 CA1 (0.41) CA1CA2CA7CA9CA12
SCHEMBL17024071 0.78 CA1 (0.50) CA1CA2CA7CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3594202-B1 SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2021-08-11 EP disclosed
EP-2489350-A1 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors Johns Hopkins University School of Medicine (US) 2012-08-22 EP disclosed
US-6784184-B2 FOR THERAPY OF RAS- ONCOGENE-DEPENDENT TUMORS, SUCH AS CANCERS OF PANCREAS, COLON, BLADDER, AND THYROID; USEFUL FOR CONTROLLING METASTASIS, SUPPRESSING ANGIOGENESIS, INDUCING APOPTOSIS, AND RAS-ASSOCIATED PROLIFERATIVE DISEASES WYETH HOLDINGS CORPORATION 2004-08-31 US disclosed
US-6605628-B1 Treatment of ras oncogene-dependent tumors; controlling metastasis, suppressing angiogenesis, inducing apoptosis WYETH HOLDINGS CORPORATION 2003-08-12 US disclosed
US-4602084-A Monoazo dyes containing a 4-substituted-2-azo-1,1'-diphenylsulfone component CIBA-GEIGY CORPORATION (US) 1986-07-22 US disclosed